ZANAMIVIR - Generic Drug Details

What are the generic drug sources for zanamivir and what is the scope of freedom to operate?

Zanamivir is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ZANAMIVIR

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	34
What excipients (inactive ingredients) are in ZANAMIVIR?	ZANAMIVIR excipients list
DailyMed Link:	ZANAMIVIR at DailyMed

Recent Clinical Trials for ZANAMIVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Oxford	Phase 2
George Washington University	Early Phase 1
Hospital Infantil de Niño Jesús de Barranquilla (HINJ)	Early Phase 1

See all ZANAMIVIR clinical trials

Pharmacology for ZANAMIVIR

Drug Class	Neuraminidase Inhibitor
Mechanism of Action	Neuraminidase Inhibitors

Medical Subject Heading (MeSH) Categories for ZANAMIVIR

Antiviral Agents

Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ZANAMIVIR

J05AH	Neuraminidase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for ZANAMIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999		RX	Yes	Yes

Expired US Patents for ZANAMIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	6,294,572
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	4,811,731
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	4,627,432
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	5,648,379
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	5,035,237

EU/EMA Drug Approvals for ZANAMIVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
GlaxoSmithKline Trading Services Limited	Dectova	Zanamivir	EMEA/H/C/004102Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance.	Authorised	no	no	no	2019-04-26

Zanamivir (Relenza): Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is zanamivir’s commercial role in antivirals?

Zanamivir is an inhaled neuraminidase inhibitor used for treatment and prophylaxis of influenza A and B. Its market dynamics are shaped by three structural forces: (1) seasonal influenza incidence and severity, (2) competitive position versus oseltamivir and later entrants, and (3) public-health procurement patterns in outbreaks.

Zanamivir’s commercial profile has historically been narrower than oral neuraminidase inhibitors because administration is device-dependent (inhalation) and because payer and prescriber preferences tend to favor oral regimens where tolerated.

How has pricing and reimbursement shaped revenue trajectory?

Across mature, seasonal respiratory markets, pricing pressure usually comes from three channels:

• Generic substitution and class competition: Where oral neuraminidase inhibitors have generic availability, zanamivir typically faces tighter formulary placement and net price erosion.
• Seasonality-driven volumes: Revenue rises and falls with influenza burden and procurement cycles rather than continuous demand.
• Bulk public-sector purchasing: In many countries, governments stockpile antivirals. During low-incidence years, procurement contracts may be rolled or reduced.

For context on competition within the influenza antiviral class:

• Oseltamivir has long been the dominant oral neuraminidase inhibitor in many markets.
• Zanamivir has remained comparatively smaller and more logistically constrained due to inhalation delivery.

What does utilization data imply about demand behavior?

Zanamivir demand historically tracks:

• Peak influenza seasons (Q4/Q1 in many Northern Hemisphere geographies).
• Outbreak intensity (spikes following high-severity seasons).
• Guideline-driven prescribing (use increases when neuraminidase inhibitor guidance favors early treatment and when resistance patterns support class use).

Where generic oral antivirals dominate, zanamivir utilization typically stays concentrated in:

• Patients with contraindications or preference against oral dosing.
• Specific clinical scenarios where inhaled delivery is chosen.
• Public health programs with existing stockpiles or procurement contracts.

How do regulatory and labeling features influence market access?

Regulatory posture supports use in influenza treatment and prophylaxis, which broadens the potential addressable population. The label scope matters for commercial outcome because prophylaxis expands the eligible high-risk window beyond acute treatment.

A key commercial implication: prophylaxis labeling can help smooth demand within influenza seasons, but it does not fully offset the cannibalization effect from competing lower-friction oral options.

What has been the competitive environment versus other influenza antivirals?

Zanamivir’s market share is strongly conditioned by:

• Class competition from oseltamivir (oral, widely adopted, generic availability in many markets).
• Shift toward neuraminidase inhibitor stewardship under resistance surveillance and pandemic preparedness frameworks.
• Entrants and substitution in influenza treatment pathways: In practice, even when alternatives exist, neuraminidase inhibitors retain a base of utilization for early-season treatment and prophylaxis.

The market remains “seasonality plus procurement,” not “evergreen blockbuster,” which limits long-term revenue compounding.

---

Financial trajectory: how the drug has performed over time

What does the public financial footprint show?

Zanamivir has not operated as a standalone earnings driver at the level of major late-stage specialty brands. Its commercial footprint has been primarily:

• Revenue contribution tied to influenza seasons.
• Stockpile-driven demand in certain jurisdictions.
• Limited sustained growth once generic oral competition and formulary restrictions tighten.

How does inhaled administration affect lifecycle economics?

From a commercial mechanics standpoint, inhaled delivery changes the economics:

• Higher friction lowers conversion from “eligible” to “treated.”
• Device logistics reduce adoption outside guideline centers and established procurement networks.
• Payer utilization management tends to push toward simpler regimens when clinically comparable.

This combination typically caps peak and slows recovery after mild seasons.

What are the key demand-sensitivity drivers?

Zanamivir revenue trajectory is most sensitive to:

• Influenza season severity (incidence and hospitalization rates drive prescribing and procurement).
• Early-treatment guidance adherence (neuraminidase inhibitors are used when started early).
• Public stockpile drawdowns and replacement cycles (often lumpy, not linear).
• Formulary and guideline positioning relative to oral alternatives.

---

Market dynamics by geography: where growth typically concentrates

Where does utilization tend to concentrate?

Zanamivir’s addressable demand concentrates where:

• Public health procurement supports neuraminidase inhibitors with existing contracts.
• Clinicians use inhaled antivirals in defined patient groups.
• Formularies retain access despite oral generic displacement.

Where does compression tend to occur?

Compression is most pronounced where:

• Oral antivirals are fully commoditized by generics and dominate procurement.
• Health systems shift toward fewer device-dependent therapies.
• Procurement standards reduce device-based antivirals during low-forecast seasons.

---

Competitive positioning: what determines pricing power

Zanamivir pricing power is constrained by:

• Therapeutic class substitutability: Neuraminidase inhibitors compete on efficacy when started early; payer prefers the lowest total cost and lowest access friction.
• Administration pathway: Oral regimens reduce barrier-to-use.
• Market maturity: Influenza antivirals face mature utilization patterns rather than growth-led adoption curves.

In this structure, zanamivir’s net revenue tends to be stable but capped, with volatility driven by influenza severity rather than brand-led expansion.

---

Key market milestones and regulatory history that matter commercially

Zanamivir was developed as an inhaled neuraminidase inhibitor for influenza treatment and prophylaxis, marketed under the Relenza brand in multiple regions. Its commercial lifecycle has been governed by:

• Ongoing influenza seasonality.
• Standard of care positioning within neuraminidase inhibitor use.
• Competition from oral neuraminidase inhibitors and later influenza therapeutic options.

For regulatory and labeling baseline:

• FDA label and regulatory documentation establish approved indications and administration expectations. (FDA prescribing information) [1]
• EMA product information covers approved uses and administration conditions for EU markets. (EMA) [2]

---

Investment and R&D implications for a zanamivir-centric view

What does zanamivir’s market behavior imply for next-wave influenza antivirals?

Zanamivir illustrates the pattern that wins in this category:

• Ease of administration and supply chain simplicity reduce friction and sustain formulary access.
• Seasonal demand and procurement cycles mean revenue forecasts must be scenario-based on influenza severity rather than on steady brand momentum.
• Competitive durability favors the lowest-cost route and broad guideline inclusion.

What does it imply for patent and exclusivity strategies?

A neuraminidase inhibitor category tends to show:

• Fast erosion when generics enter oral competitors.
• Value leakage if the molecule or formulation does not reduce administration friction.
• Higher ROI potential when next entrants improve endpoint-driven differentiation that changes guideline behavior, not only convenience.

---

Key Takeaways

• Zanamivir’s market dynamics are driven by influenza season severity, early-treatment prescribing patterns, and public procurement cycles rather than sustained growth.
• Net revenue trajectory is constrained by competition from oral neuraminidase inhibitors and payer preference for lower-friction administration.
• Inhaled-device administration lowers adoption breadth and typically limits pricing power and long-term revenue compounding versus oral options.
• Commercial performance is best modeled as lumpy, seasonal, and procurement-influenced, with compression risk increasing as oral competitors become commoditized.

---

FAQs

1) Is zanamivir a treatment-only product or does it have prophylaxis demand?

It has both treatment and prophylaxis indications, which expands the eligible patient window during influenza seasons. (FDA prescribing information) [1]

2) Why does zanamivir’s market scale usually lag oral neuraminidase inhibitors?

Inhaled delivery adds device and administration friction, while oral options have broader ease-of-use and often face generic-driven pricing pressure.

3) What drives quarter-to-quarter volatility for zanamivir revenue?

Influenza season severity and timing, plus public-sector stockpile drawdowns and replenishment cycles, create uneven demand across periods.

4) Does resistance influence zanamivir utilization?

Yes, resistance surveillance and guideline stewardship affect class utilization, shifting use toward neuraminidase inhibitors when appropriate and away when not.

5) Is zanamivir’s commercialization model closer to seasonal procurement or chronic therapy?

It is closer to seasonal procurement and treatment spikes, with demand concentrated around influenza peaks rather than ongoing year-round utilization.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Relenza (zanamivir) prescribing information. FDA.
[2] European Medicines Agency. (n.d.). Relenza (zanamivir) product information. EMA.